Answer: c. 2 pyruvate molecules
Explanation:
Glycolysis is the first step it the cell respiration cycle. It turns one molecule of glucose into two molecules of pyruvate by a series of reactions catalyzed by different enzymes.
It starts by using 2 ATP to turn glucose into fructose-1,6-bisphosphate, which then divides in two and releases 4 ATP when it turns into two pyruvate molecules.
Thus glycolysis consumes 2 ATP and releases 4 ATP (giving a net gain of 2 ATP) and 2 pyruvate molecules.
They relate because they both have to do with the behavioral patterns of the cycle of life. essentially they both are related to way things transform into one another
Write a new hypothesis and conduct new experiments to explore the matter. Thus, option "B" is correct.
<h3 /><h3>What is the Hypothesis?</h3>
Hypothesis
The formulation of hypotheses is one of the key steps in the scientific method.
Hypotheses are usually tested using experiments and are usually accepted or rejected depending on the outcome of the experiments.
If a hypothesis is rejected, it does not mean that the entire subject is abandoned. Rather, new hypotheses may be formed and experiments conducted to further explore the subject.
More hypotheses can be found here:
brainly.com/question/23056080
#SPJ1
Answer:
A. organ.. B. Species
Explanation:
1. parts that make up organism are called as organs
2. a group of similar organisms that can successfully interbreed called as species.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
